Vitamin D supplementation and neurofilament light chain in multiple sclerosis.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of multiple sclerosis, published as a randomized controlled trial.

The effect of vitamin D supplementation on the disease course of multiple sclerosis (MS) is not established.

Neurofilament light chain (NFL) is a sensitive marker of axonal degeneration.

Who Took Part

The study group was 71 patients.

By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, both men and women.

Serum levels of NFL were measured at baseline, week 48 and week 96 with a single molecule (Simoa) assay in 69 of these patients.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Dietary Supplements, Intermediate Filaments, Multiple Sclerosis, Relapsing-Remitting, Vitamin D and Vitamins.

The authors tagged it with the keywords clinical trial and neurofilament light chain.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 71 patients in people with multiple sclerosis.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Acta neurologica Scandinavica), a journal based in Denmark.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Multiple sclerosis research.